Meditech boosted by Phase II results
19 August, 2004 by Renate KrelleWith all patients in the first stage of its Phase II HyCamp clinical trial escaping the gastrointestinal side-effects normally associated with standard colon cancer treatment irinotecan, Meditech (ASX:MTR) has announced it will forge ahead with second stage of its trial.
A Conneticut Yankee in Prana's court
17 August, 2004 by Graeme O'NeillPrana Biotechnology’s (ASX:PBT, NASDAQ:PRAN ) new American CEO Jonas Alsenas began taking an interest in the company several years ago, when he felt the faint tremors of a paradigm shift in the Alzheimer’s disease research field.
Somnomed propels itself towards the market
09 August, 2004 by Melissa TrudingerSydney-based company Somnomed is preparing to list on the ASX later this month, with an IPO expected to raise AUD$12 million through the sale of 40 million shares at $0.30 per share.
New test developed for oesophageal cancer
04 August, 2004 by Staff WritersResearchers at the Wolfson Institute for Biomedical Research at University College London have developed a test to detect cancer of the oesophagus which could improve survival rates.
CBio gears up for Phase II trials of autoimmune drug
27 July, 2004 by Melissa TrudingerQueensland biotech CBio presented its Phase I clinical trial results at the World Congress of Immunology in Montreal last week, and is raising capital and readying itself for Phase II trials.
QIMR, Tissue Therapies make cell supply deal
22 July, 2004 by Renate KrelleResearchers at the Queensland Institute of Medical Research (QIMR) have struck a formal deal with recently-listed Tissue Therapies (ASX:TIS) to boost the yield and quality of dendritic cells for their cancer vaccine using the company's cellular growth enhancer VitroGro.
New trials planned for Melbourne team's cancer vaccine
21 July, 2004 by Graeme O'NeillIt began as a routine trial of a therapeutic vaccine for melanoma, but it had a spectacular and unexpected outcome -- all but two of the 19 patients treated with the vaccine are still alive two years after beginning treatment.
Cancer researcher humbled by major award
21 July, 2004 by Susan WilliamsonDr Susan Clark from the Sydney Cancer Centre and the Garvan Institute has been awarded a major international prize for her contribution to DNA methylation research over the last 10 years.
Medica morphs into Cytopia, wins record ARC grant
21 July, 2004 by Melissa Trudinger and Renate KrelleMedica Holdings officially became Cytopia (ASX:CYT) this week, as it took the next big step from being a biotech investment company to a biotech company in its own right.
Psiron license triggers $2.5m raising
13 July, 2004 by Renate KrelleSydney-based biotech Psiron (ASX:PXS) is putting its house in order -- having announced its intention to license oncolytic enteroviruses technology from University of Newcastle alumnus Virotarg, the company today said the license would trigger an AUD$2.5 million capital raising.
Acrux signs CSL deal, waits to list
07 July, 2004 by Melissa TrudingerAcrux has signed an agreement with CSL for the distribution of Acrux's testosterone MDTS (metered dose transdermal spray) treatment in Australia and New Zealand.
AustCancer subsidiary signs distribution deal
06 July, 2004 by Renate KrelleACT US, the US subsidiary of oncology specialist Australian Cancer Technology ("AustCancer") (ASX: ACU) has signed a distribution deal for its revisys range of nutritional supplements.
Aldara gets green light for actinic keratosis
06 July, 2004 by Staff WritersUS regulators have given the green light for doctors to prescribe Minnesota-based 3M's Aldara for precancerous skin lesions called actinic keratosis. 3M is also awaiting approval for Aldara's use against a common form of non-melanoma skin cancer, superficial basal cell carcinoma.
New epilepsy patent for Bionomics
05 July, 2004 by Renate KrelleAdelaide epilepsy specialist Bionomics (ASX:BNO) has announced that its patent covering a link between the nicotinic acetylcholine receptor ion channel subunit and epilepsy has been accepted in New Zealand.
Life Therapeutics signs MOU with UK's BioProducts
30 June, 2004 by Melissa TrudingerLife Therapeutics, the company formerly known as Gradipore (ASX: GDP), has signed a memorandum of understanding with UK company Bio Products Laboratories (BPL) over the potential acquisition of a recombinant human anti-D immunoglobulin (rAnti-D).
